Skip to main content

NG-641-01 NG-641-01: A Multicentre, Open-label, Non-randomised First in Human Study of NG-641, an Oncolytic Transgene Expressing Adenoviral Vector, in Patients With Metastatic or Advanced Epithelial Tumours (STAR)

NCT04053283

NG-641-01: A Multicentre, Open-label, Non-randomised First in Human Study of NG-641, an Oncolytic Transgene Expressing Adenoviral Vector, in Patients With Metastatic or Advanced Epithelial Tumours (STAR)

Associated Conditions

Melanoma

Principal Investigator

George Simon

Sponsor

PsiOxus Therapeutics Ltd

The purpose of this research study is to find out the following: (1) What effects, good and/or bad, treatment with NG-641 has on you and your cancer; (2) The amount of NG-641 that can be given and/or the best timing between doses; (3) What happens to the NG-641 virus and the proteins it makes in your body

This study is currently enrolling.